CG Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
Buy Rating Justified for CG Oncology's Cretostimogene Due to Superior Safety Profile and Competitive Efficacy
Goldman Sachs Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $52
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amid Competitive Landscape and Strong Clinical Results
CG Oncology Price Target Announced at $65.00/Share by Roth MKM
CG Oncology Initiated at Buy by Roth MKM
CG Oncology Analyst Ratings
Roth MKM Initiates Coverage On CG Oncology With Buy Rating, Announces Price Target of $65
Morgan Stanley Keeps Their Buy Rating on CG Oncology, Inc. (CGON)
Buy Rating for CG Oncology: Promising CG0070 Data Signals Strong Market Potential
Analysts' Opinions Are Mixed on These NA Stocks: Solventum Corporation (SOLV) and CG Oncology, Inc. (CGON)
CG Oncology Analyst Ratings
B of A Securities Initiates Coverage On CG Oncology With Buy Rating, Announces Price Target of $65
Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)
CG Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target